Literature DB >> 6764512

Loperamide modifies Escherichia coli, heat-stable enterotoxin-induced intestinal secretion.

J Watt, D C Candy, B Gregory, J H Tripp, J T Harries.   

Abstract

We have shown previously that loperamide, an opiate analogue, inhibits cholera-toxin- and prostaglandin E2-induced secretion in the rat small intestine. In these studies loperamide modified secretion induced by partially purified Escherichia coli, heat-stable enterotoxin in infant mice. The drug was effective whether administered before or after established secretion. These experiments provide further suggestive evidence that loperamide has a broad spectrum of antisecretory activity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6764512     DOI: 10.1097/00005176-198212000-00023

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  5 in total

Review 1.  Pathogenesis and pharmacology of diarrhea.

Authors:  L Ooms; A Degryse
Journal:  Vet Res Commun       Date:  1986-09       Impact factor: 2.459

2.  Secretagogue-induced changes in membrane calcium permeability in chicken and chinchilla ileal mucosa. Selective inhibition by loperamide.

Authors:  E B Chang; D R Brown; N S Wang; M Field
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

3.  Reversal of the biological activity of Escherichia coli heat-stable enterotoxin by disulfide-reducing agents.

Authors:  M M ElDeib; C R Dove; C D Parker; T L Veum; G M Zinn; A A White
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

4.  Loperamide in acute diarrhoea in childhood: results of a double blind, placebo controlled multicentre clinical trial. Diarrhoeal Diseases Study Group (UK).

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1984-11-10

5.  Rotavirus infection increases intestinal motility but not permeability at the onset of diarrhea.

Authors:  Claudia Istrate; Marie Hagbom; Elena Vikström; Karl-Eric Magnusson; Lennart Svensson
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.